Department of Pathology, CHU UCL Namur, Site Godinne, Avenue Docteur G. Thérasse 1, 5530, Yvoir, Belgium.
Breast Clinic, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.
Virchows Arch. 2021 Jul;479(1):33-43. doi: 10.1007/s00428-021-03040-6. Epub 2021 Jan 27.
Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease in terms of morphological characteristics, protein expression profiles, genetic abnormalities, and potential for progression. Molecular heterogeneity has been extensively studied in DCIS. Yet morphological heterogeneity remains relatively undefined. This study investigated morphological intratumor heterogeneity in a series of 51 large DCIS. Nuclear atypia, DCIS architecture, necrosis, calcifications, stromal architecture, and stromal inflammation were assessed in one biopsy slide and three representative slides from each corresponding resection. For each histopathological feature, a histo-score was determined per slide and compared between the biopsy and the resection, as well as within a single resection. Statistical analysis comprised of Friedman tests, post hoc Wilcoxon tests with Bonferroni corrections, Mann-Whitney U tests, and chi-square tests. Despite substantial morphological heterogeneity in around 50% of DCIS, the histopathological assessment of the biopsy did not statistically significantly differ from the resection. Morphological heterogeneity was not significantly associated with patient age, DCIS size, or type of surgery, except for a weak association between heterogeneous stromal inflammation and smaller DCIS size. At the group level, the degree of heterogeneity did not significantly affect the representativity of a biopsy. At the individual patient level, however, the presence of necrosis, intraductal calcifications, myxoid stromal changes, and high-grade nuclear atypia was underestimated in a minority of DCIS patients. This study confirms the presence of morphological heterogeneity in DCIS for all six evaluated histopathological features. This should be kept in mind when taking biopsy-based treatment decisions for DCIS patients.
乳腺导管原位癌 (DCIS) 在形态学特征、蛋白表达谱、遗传异常和进展潜能方面存在异质性。分子异质性已在 DCIS 中得到广泛研究。然而,形态学异质性仍然相对未定义。本研究调查了 51 例大型 DCIS 系列中肿瘤内形态学异质性。在一个活检切片和每个相应切除的三个代表性切片中评估核异型性、DCIS 结构、坏死、钙化、基质结构和基质炎症。对于每个组织病理学特征,根据幻灯片确定一个组织学评分,并比较活检与切除之间以及单个切除内的评分。统计分析包括 Friedman 检验、后验 Wilcoxon 检验与 Bonferroni 校正、Mann-Whitney U 检验和卡方检验。尽管大约 50%的 DCIS 存在明显的形态学异质性,但活检的组织病理学评估与切除之间没有统计学显著差异。形态学异质性与患者年龄、DCIS 大小或手术类型无关,除了间质炎症的异质性与较小的 DCIS 大小之间存在弱相关性。在组水平上,异质性程度不会显著影响活检的代表性。然而,在个体患者水平上,少数 DCIS 患者的坏死、导管内钙化、黏液样基质变化和高级别核异型性存在低估。本研究证实了所有六种评估的组织病理学特征中 DCIS 存在形态学异质性。在为 DCIS 患者做出基于活检的治疗决策时应考虑到这一点。